Tag - SYBX

Developments

Synlogic gets FDA fast track to treat phenylketonuria

The FDA granted fast track designation to Synlogic’s (NASDAQ:SYBX) labafenogene marselecobac (previously known as SYNB1934) for the treatment of phenylketonuria (PKU). Labafenogene marselecobac also has received rare...

July 11, 2023

Developments

Synlogic initiates pivotal study for phenylketonuria

Synlogic (NASDAQ:SYBX) initiated Synpheny-3, a global, Phase 3 study evaluating the efficacy and safety of SYNB1934 as a potential treatment for phenylketonuria (PKU), a rare inherited disorder that causes an amino...

June 5, 2023

Feature

Synlogic advancing novel biotherapeutics based on synthetic biology

Synlogic (NASDAQ:SYBX) is advancing a new class of biotherapeutics, known as Synthetic Biotics, targeting validated biology in rare metabolic and immunological diseases.

June 7, 2022

Markets

BTIG cuts Synlogic PT to $9 from $22

BTIG reduced its price target for Synlogic (NASDAQ:SYBX) to $9 from $22 after the company discontinued development of SYNB1020, an early-stage clinical product candidate for the treatment of hyperammonemia. The stock...

August 20, 2019

Tag - SYBX

Synlogic gets FDA fast track to treat phenylketonuria

Synlogic initiates pivotal study for phenylketonuria

Synlogic advancing novel biotherapeutics based on synthetic biology

BTIG cuts Synlogic PT to $9 from $22

General

More